Q3 Loss Widens to $78M, Missing Estimates as Operating Expenses Hit $85M
FDMT sits 73% above its 52-week low of $6.96.
Summary
4D Molecular Therapeutics posted a Q3 net loss of $78.056 million, or -$1.08 per basic share, worse than the IBES estimate of -$74.2 million. Revenue of $4.145 million beat the $2.7 million estimate, but operating expenses of $85.363 million drove an operating loss of $81.218 million versus the -$79 million consensus. The loss widened from the $72.9 million net loss reported in Q2, when R&D spending rose 42% to $68.3 million. Cash and marketable securities stood at $430.6 million as of the last quarterly filing, giving the company at least a year of runway while it funds the 4SIGHT Phase 3 trial of 4D-150 in diabetic macular edema, which enrolled its first patients in late September.
At the time of this announcement, FDMT was trading at $12.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $669.3M. The 52-week trading range was $6.96 to $16.93. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.